Takeda (TAK) announced that the FDA has approved Gammagard Liquid ERC with less than or equal to two microgram/mL IgA in a 10% solution, the only ready-to-use liquid immunoglobulin therapy with low immunoglobulin A content, as replacement therapy for people two years of age and older with primary immunodeficiency.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.